Revenue: As of FY2025 Q1, the actual value is USD 16.64 M, missing the estimate of USD 19.3 M.

EPS: As of FY2025 Q1, the actual value is USD -0.32, missing the estimate of USD -0.2071.

EBIT: As of FY2025 Q1, the actual value is USD -15.6 M.

Revenue

• Total revenue for the first quarter of 2025 was $16.6 million, a decrease of 9.8% compared to $18.4 million in the prior year period.

Gross Margin

• Gross margin improved to 59.3% in the first quarter of 2025, compared to 45.7% in the prior year period.

Operating Expenses

• Operating expenses were $23.3 million for the first quarter of 2025, a reduction of 22.3% from $30.0 million in the prior year period.

Operating Loss

• Operating loss was $13.4 million for the first quarter of 2025, an improvement of 37.9% compared to $21.6 million in the prior year period.

Net Cash Used in Operating Activities

• Net cash used in operating activities decreased by $13.6 million to $7.2 million in the first quarter of 2025, compared to $20.8 million in the prior year period.

Cash, Cash Equivalents, and Marketable Securities

• As of March 31, 2025, Akoya had $27.5 million in cash, cash equivalents, and marketable securities.

Unique Metrics

• The installed base of instruments increased by 12.0% year-over-year, ending the quarter with 1,359 instruments (410 PhenoCyclers, 949 PhenoImagers).
• Total publications citing Akoya’s technology increased by 44.7% year-over-year, reaching 1,891 publications.

Outlook / Guidance

• Akoya will not be hosting an earnings conference call or providing forward-looking guidance due to the pending acquisition by Quanterix Corporation.